| |
| |
|
| Insider
Information: |
Love Ted W |
| Relationship: |
Director |
| City: |
Sunnyvale |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
10 |
|
| Direct
Shares |
252,099 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$2,546,810 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
252,099 |
|
|
| Total
Value |
$2,546,810 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Nuvelo Inc |
ABIO |
Director |
2008-05-30 |
3,580 |
2004-02-27 |
0 |
Premium* |
|
|
Onyx Pharmaceuticals Inc |
ONXX |
EVP, R&D and Tech. Ope... |
2012-07-25 |
77,756 |
2010-02-01 |
0 |
Premium* |
|
|
Santarus Inc |
SNTS |
Director |
2014-01-02 |
0 |
2012-03-09 |
0 |
Premium* |
|
|
Amicus Therapeutics Inc |
FOLD |
Director |
2020-06-04 |
131,000 |
2014-03-12 |
0 |
Premium* |
|
|
Global Blood Therapeutics, Inc. |
GBT |
President and CEO, Dir... |
2022-10-05 |
0 |
2022-10-05 |
0 |
Premium* |
|
|
Cascadian Therapeutics, Inc |
CASC |
Director |
2018-03-09 |
0 |
2015-09-05 |
0 |
Premium* |
|
|
Portola Pharmaceuticals Inc |
PTLA |
Director |
2020-07-02 |
0 |
2019-09-18 |
0 |
Premium* |
|
|
Royalty Pharma Plc |
RPRX |
Director |
2023-06-23 |
36,941 |
|
0 |
Premium* |
|
|
Seagen Inc |
SGEN |
|
2023-12-14 |
0 |
2020-08-17 |
0 |
Premium* |
|
|
Gilead Sciences Inc |
GILD |
Director |
2024-05-08 |
2,822 |
2024-02-02 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
123 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 5
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| FOLD |
Amicus Therapeutics Inc |
Director |
– • – |
2017-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
5,814 |
5,814 |
0 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • – |
2017-06-13 |
4/A |
A |
$0.00 |
$0 |
D/D |
5,814 |
147,814 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2017-06-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,058 |
37,878 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2017-06-24 |
4 |
D |
$3.78 |
$8,562 |
D/D |
(2,265) |
35,613 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2017-09-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,375 |
37,988 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2017-09-24 |
4 |
D |
$3.94 |
$2,340 |
D/D |
(594) |
37,394 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2018-03-09 |
4 |
D |
$0.00 |
$0 |
D/D |
(37,394) |
0 |
0 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • – |
2018-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,081 |
8,895 |
0 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • – |
2019-06-27 |
4 |
A |
$0.00 |
$0 |
D/D |
6,250 |
125,145 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
Director |
– • – |
2019-09-18 |
4 |
A |
$0.00 |
$0 |
D/D |
8,294 |
8,294 |
0 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • – |
2020-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
5,855 |
131,000 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
Director |
– • – |
2020-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
7,281 |
15,575 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
Director |
– • – |
2020-07-02 |
4 |
D |
$18.00 |
$280,350 |
D/D |
(15,575) |
0 |
0 |
- |
|
| RPRX |
Royalty Pharma Plc |
Director |
– • – |
2020-07-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
10,000 |
|
% |
|
| RPRX |
Royalty Pharma Plc |
Director |
– • – |
2020-08-13 |
4 |
A |
$0.00 |
$0 |
D/D |
7,280 |
17,280 |
0 |
- |
|
| SGEN |
Seagen Inc |
Director |
– • – |
2020-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
1,799 |
1,799 |
0 |
- |
|
| SGEN |
Seagen Inc |
Director |
– • – |
2021-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,402 |
3,201 |
0 |
- |
|
| RPRX |
Royalty Pharma Plc |
Director |
– • – |
2021-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
5,726 |
22,866 |
0 |
- |
|
| SGEN |
Seagen Inc |
Director |
– • – |
2022-05-13 |
4 |
A |
$0.00 |
$0 |
D/D |
1,503 |
4,704 |
0 |
- |
|
| RPRX |
Royalty Pharma Plc |
Director |
– • – |
2022-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
6,328 |
29,194 |
0 |
- |
|
| SGEN |
Seagen Inc |
Director |
– • – |
2023-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
2,044 |
6,748 |
0 |
- |
|
| RPRX |
Royalty Pharma Plc |
Director |
– • – |
2023-06-23 |
4 |
A |
$0.00 |
$0 |
D/D |
7,747 |
36,941 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
Director |
• • – |
2024-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
512 |
512 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
Director |
• • – |
2024-05-08 |
4 |
A |
$0.00 |
$0 |
D/D |
2,310 |
2,822 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
EVP, R&D |
• – – |
2010-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
16,500 |
31,850 |
0 |
- |
|
123 Records found
|
|
Page 2 of 5 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
